NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Concert Pharmaceuticals Inc (NASDAQ:CNCE) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.72) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.85) by $0.13. The biotechnology company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%. View Concert Pharmaceuticals' Earnings History.

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Concert Pharmaceuticals.

7 brokerages have issued 12-month price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $8.00 to $25.00. On average, they expect Concert Pharmaceuticals' share price to reach $17.00 in the next twelve months. This suggests a possible upside of 115.7% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

Press coverage about CNCE stock has been trending somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Concert Pharmaceuticals.

Concert Pharmaceuticals saw a decrease in short interest during the month of October. As of October 15th, there was short interest totalling 599,700 shares, a decrease of 35.4% from the September 15th total of 927,900 shares. Based on an average trading volume of 227,000 shares, the short-interest ratio is currently 2.6 days. Approximately 2.8% of the shares of the stock are sold short. View Concert Pharmaceuticals' Current Options Chain.

Some companies that are related to Concert Pharmaceuticals include Aprea Therapeutics (APRE), Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), Urogen Pharma (URGN), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Collegium Pharmaceutical (COLL), Kura Oncology (KURA), Cara Therapeutics (CARA), Intra-Cellular Therapies (ITCI), Clovis Oncology (CLVS), Omeros (OMER), Vectura Group (VEGPF), TherapeuticsMD (TXMD) and Kadmon (KDMN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Eiger Biopharmaceuticals (EIGR), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Anavex Life Sciences (AVXL), Conatus Pharmaceuticals (CNAT) and Corbus Pharmaceuticals (CRBP).

Concert Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (6.44%), State Street Corp (1.69%), Millennium Management LLC (1.54%), California Public Employees Retirement System (0.65%), Russell Investments Group Ltd. (0.53%) and Man Group plc (0.37%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.

CNCE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Man Group plc, Barclays PLC and Alps Advisors Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, State Street Corp, BB&T Securities LLC, Virtu Financial LLC, California Public Employees Retirement System and Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van and Richard Aldrich. View Insider Buying and Selling for Concert Pharmaceuticals.

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNCE stock can currently be purchased for approximately $7.88.

Concert Pharmaceuticals has a market capitalization of $187.87 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]